

<b>Policy</b>	<b>MM-023</b>
<b>Effective Date</b>	<b>09/01/2024</b>
Reviewed/Revised Date	03/23/2026
Next Review Date	03/23/2026
Origination Date	01/01/2024
Originated Department	Medical Management

### Cell-Free (cfDNA) Testing for Fetal Aneuploidy

<b>Audience</b>
Providers, Members, Brokers, MHC

<b>Purpose</b>
<p>Medical policies provide general support for applying Mountain Health Co-Op member policy document coverage decisions, and the member-specific benefit plan document must be referenced. The terms of the member-specific Policy document may differ from the standard benefit plan based on this medical policy. If there is a conflict between a member-specific policy document and the Mountain Health Co-Op medical policy, the document supersedes this policy. Any person(s) applying this medical policy must identify member eligibility, the member-specific policy document, and related policies or guidelines before applying this medical policy, including the existence of any state or federal guidance. Mountain Health Co-Op medical policies are designed for informational purposes only and are not an authorization, explanation of benefits, or contract. Receipt of benefits is subject to the satisfaction of all terms and conditions of the member-specific policy document coverage. Mountain Health Co-Op reserves the sole discretionary right to modify all policies and guidelines at any time.</p>

<b>Definition</b>
<p>Chromosomal abnormalities can complicate pregnancy. Some chromosomal abnormalities, such as trisomy (having three copies of a given chromosome or chromosome segment in each somatic cell rather than the normal number of 2), occur more commonly in children of women older than age 35 when they become pregnant and if certain other high-risk indicators exist. The most common trisomy conditions include Trisomy 21 (Downs syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome).</p>

To help families and pregnant women determine if these conditions may exist, various prenatal testing is undertaken, particularly in high-risk individuals. Currently, several different blood tests in combination with nuchal translucency assessment by ultrasound are the standard of care for screening for the presence of trisomy. Either amniocentesis or chorio-villous sampling is then performed as a definitive test to determine if a trisomy condition is truly present.

With the discovery of cell free fetal DNA circulating in maternal blood new methods to test for trisomy have been developed. There are a number of companies currently providing this testing including Sequenom [Materniti21], Natera [Panorama], Roche/Ariosa [Harmony] and others. These tests or assays are based on the purification of cell-free DNA from maternal plasma applying recent high-tech developments in sequence (and bioinformatics) analysis of DNA fragments. It is not known whether or to what extent the results of these and other testing technologies would be in agreement.

It is hoped that the use of these more definitive tests to detect fetal trisomy will result in the need for fewer invasive procedures such as amniocentesis or chorio-villous sampling with an associated reduction in procedure complications resulting in miscarriages and loss of the pregnancy.

### **Regulatory Status**

In April 2021, the FDA released a statement titled “Genetic Non-Invasive Prenatal Screening Tests May Have False Results: FDA Safety Communication,” detailing safety concerns regarding NIPS tests outside of standard screening purposes. Specifically, they reinforced that NIPS tests are laboratory-developed tests not regulated by the FDA and should be confined to screenings rather than diagnoses. “The FDA has not evaluated the accuracy and performance of NIPS tests, and these tests can give false results, such as reporting a genetic abnormality when the fetus does not have one. NIPS tests are screening tests, which means the NIPS test may only tell you the risk of the fetus having certain genetic abnormalities. They are not diagnostic tests generally used to confirm or rule out a suspected genetic abnormality more definitively.” Additionally, “The FDA recommends that patients discuss the benefits and risks of NIPS tests with a genetic counselor or other health care provider before deciding to get these tests. Patients should also discuss the results of NIPS tests with a genetic counselor or other health care provider before making any decisions about their pregnancy. Healthcare providers should be aware of the risks and limitations of using these screening tests. They should not use the results from these tests alone to diagnose chromosomal (genetic) abnormalities or disorders” (FDA, 2022).

Many labs have developed specific tests they must validate and perform in-house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare & Medicaid Services (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U.S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

## Policy/Procedure

1. The application of coverage criteria depends on an individual's benefit coverage at the time of the request.
2. For pregnant individuals who desire information on the risk of having a child with fetal aneuploidy, the following screening tests to detect fetal aneuploidy of chromosomes 13, 18, and 21 is considered **MEDICALLY NECESSARY**:
  - 2.1 First-trimester (defined as 11 – 14 weeks) screening incorporating maternal serum markers (hCG, PAPP-A with NT).
  - 2.2 Second-trimester (15 – 22 weeks) screening incorporating triple maternal serum markers (hCG, AFP, uE3 with NT) and quad maternal serum markers (hCG, AFP, uE3, DIA with NT).
  - 2.3 First (11-14 weeks) and second (15 – 22 weeks) trimester integrated screening incorporating maternal serum markers (PAPP-A with NT) and quad maternal serum markers (hCG, AFP, uE3, DIA with NT).
  - 2.4 First (11-14 weeks) and second (15 – 22 weeks) trimester sequential screening incorporating maternal serum markers (PAPP-A, hCG with NT) and quad maternal serum markers (hCG, AFP, uE3, DIA with NT).
  - 2.5 First (11-14 weeks) and second (15 – 22 weeks) trimester contingent screening incorporating maternal serum markers (PAPP-A, hCG with NT); if positive, quad maternal serum markers (hCG, AFP, uE3, DIA with NT).
3. For pregnant individuals who desire information on the risk of having a child with fetal aneuploidy, non-invasive prenatal screening (NIPS) to detect fetal aneuploidy of chromosomes 13, 18, 21, X, and Y (singleton or twin pregnancies of at least 10 weeks gestation) is considered **MEDICALLY NECESSARY**.
4. For pregnant individuals who desire information on the risk of having a child with fetal aneuploidy or to pursue additional confirmatory testing of equivocal or positive results from the above testing, karyotyping to confirm fetal aneuploidy is considered **MEDICALLY NECESSARY**.
5. To detect fetal aneuploidy, the use of the “penta” screen (hCG, AFP, uE3, DIA with NT, and hyperglycosylated hCG) is considered **NOT MEDICALLY NECESSARY**.
6. Screening for the detection of fetal aneuploidies is considered **NOT MEDICALLY NECESSARY** in any of the following situations:
  - 6.1 Parallel or simultaneous testing with multiple screening methodologies for fetal aneuploidy.
  - 6.2 For the screening of pregnant individuals with higher-order multiple gestation pregnancies.
  - 6.3 Repeat screening for pregnant individuals with negative screening results.
  - 6.4 To detect other chromosomal abnormalities (e.g., microdeletion syndromes, unbalanced translocations, deletions, duplications) not addressed above.
  - 6.5 For the determination of fetal sex.
7. ***The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for diagnosing and treating an individual's illness.***

**7.1** For diagnosing fetal aneuploidy, single-cell genotyping in trophoblasts isolated from maternal serum (e.g., Luna Prenatal Test) is considered **NOT MEDICALLY NECESSARY**.

## **8. Clinical Rationale**

- 8.1** A review of the literature performed in August 2012 identified 3 systematic reviews and 23 primary studies. A systematic review from the California Technology Assessment Forum (CTAF) summarized well the current testing methods and sensitivity and specificity rates of seven studies conducted to evaluate cfDNA's use for fetal aneuploidy screening. The analysis affirmed the accuracy of cfDNA for detecting Trisomy 21. Limitations cited of the studies were the low number of patients of normal patients enrolled in the studies, which may influence the specificity; the studies only included high-risk women, a lack of direct comparison to current screening methods for aneuploidy, and lack of data outside of an investigational study.
- 8.2** Most published evidence on cfDNA is based on studies conducted on high-risk populations. There is now data on the performance of cfDNA in the general obstetric population. One study conducted in 2013 compared the clinical performance of cfDNA in detecting trisomies 21, 18 and 13 in 146,958 pregnancies in low-risk versus high-risk pregnancies. There was no significant difference in test performance between the 72 382 high-risk and 40 287 low-risk subjects (sensitivity, 99.21% vs 98.97% (P = 0.82); specificity, 99.95% vs 99.95% [P = 0.98]). However, due to the lower prevalence of aneuploidy in low-risk pregnancies (e.g., in women under the age of 35), the positive predictive value of this test is lower in the general obstetric population.
- 8.3** Two articles seminal to the determination of clinical validity are the studies of Palomaki et al. and Bianchi et al. Each evaluated 1 of the commercially available tests, Palomaki assessing the MaterniT21™ test and Bianchi assessing the Verify™ prenatal test. Each study demonstrated the detection for aneuploidies has high sensitivity and specificity for Trisomy 21 approaching 100% under the study conditions. Additionally, sensitivity and specificity for trisomies 13 and 18 are about 78% and 97% respectively, depending on the test method/vendor. Below are the abstracts of 2 major prospective studies.
- 8.4** Another study by Palomaki et al, in 2017, assessed the clinical utility of cfDNA-based screening for aneuploidies offered through primary obstetrical care providers to a general pregnancy population. Among 2,681 tests reported, 16 women (0.6%) were screen-positive for trisomy 21, 18 or 13. Twelve were confirmed (PPV, 75%) and four were false-positives (0.15%). Of 150 test failures (5.6%), 79% had a negative serum or subsequent cfDNA test. There were no reported cases of aneuploidy among cfDNA test failures. This first clinical utility study of cfDNA screening found higher uptake rates, patient understanding of basic concepts, and easy incorporation into routine obstetrical practices.
- 8.5** Additionally, there are concerns about how the testing will fit into existing clinical care pathways. A recently published economic study, funded by the manufacturer of the Verify prenatal test suggested the greatest benefit of the testing may come from a reduction in miscarriages due to invasive testing. In the modeled population,

invasive diagnostic-induced miscarriages are reduced by 66%. When an invasive procedure is not used following a positive test result, miscarriages are further reduced to about 81%. The study also suggests annual savings related to prenatal screening and diagnosis of fetal aneuploidy to be about 1%. These measures are most impacted by the cost of the cfDNA test; secondarily by the cost of amniocentesis, the rate of second trimester ultrasound and the specificity of prenatal screening.

- 8.6** Some evidence supports the statistical and clinical validity of fetal cell-free DNA as a means of identifying aneuploidy issues in high risk populations. Many unanswered questions remain regarding its exact clinical role, but evidence exists which supports use of the test in the appropriate setting has potential cost effectiveness and improves quality of life.
- 8.7** A study by Grace et al, in 2016, found that since 2011 the American College of Obstetrics and Gynecology (ACOG) and the Society for Maternal Fetal Medicine (SMFM), the International Society for Prenatal Diagnosis (ISPD), the National Society for Genetic Counselors, and the American College of Medical Genetics and Genomics only recommended cfDNA screening in singleton pregnancies, of women who are considered “high risk” defined by: 1. Their maternal age is 35 or older at time of birth; 2. Having a previous effected pregnancy with a trisomy; 3. Having a positive first or second trimester screening; 4. Having an abnormal ultrasonic finding; and 5. Parental balanced Robertsonian translocation that increases the risk of Trisomy 21 or 13. As more research became available validating the performance of cfDNA screening in general obstetric populations, some societies softened previous recommendations to limit cfDNA screening to high-risk patient populations (i.e., ISPD and The American College of Medical Genetics and Genomics).
- 8.8** In 2015 ACOG and SMFM published a joint committee opinion on the use of cfDNA testing concluded that “given the performance of traditional screening methods and the limitations of cfDNA, conventional screening methods remain the most appropriate choice for first-line screening for most women in the general obstetric population.” However, if low risk women choose to have the screening they should have pre and post-test counseling of the limitations and benefits and should not make any pregnancy management decisions, including termination based on this test alone.
- 8.9** A 2015 statement from the Society for Maternal-Fetal Medicine (SMFM), indicates their recommendation for cell-free DNA aneuploidy testing should not be offered to all pregnant women, only “high risk” pregnancies described above. When it comes to patient autonomy, SMFM believes any woman who requests additional testing should be given the option of this test, even though professional societies do not recommend testing in “low risk” pregnancies. Furthermore, SMFM suggests that insurance coverage should not be required for any “low risk” pregnancies.
- 8.10** ACOG recently modified its guidance regarding cfDNA testing for fetal aneuploidy. It now states “Cellfree DNA screening can be performed in twin pregnancies. Overall, performance of screening for trisomy 21 by cell-free DNA in twin pregnancies is encouraging, but the total number of reported affected cases is small. Given the small number of affected cases it is difficult to determine an

accurate detection rate for trisomy 18 and 13.” These recommendations are based on limited evidence and Hayes in their 2022 update noted the benefits of this testing in a low risk population remains uncertain.

- 8.11** The 2022 Hayes clinical utility report, goes on to note, over the past few decades, the incidence of multifetal gestations has increased remarkably in the United States. Nonetheless, maternal serum screening has several limitations. In twin gestations, conventional maternal serum screening can be complicated by the presence of analytes from the normal and affected fetuses. Analyte levels are effectively averaged together, masking the abnormal levels from the affected fetus. Several aneuploidy screening methods are available for twin gestations, summarized, along with clinical performance for trisomy 21. However, there is only limited information available in screening for trisomy 18 and 13.
- 8.12** CfDNA provides information on the three most common aneuploidies but has not been validated for screening of microdeletions, thus cannot be recommended for clinical use. Given the low prevalence of microdeletion disorders, the significance of the results from cfDNA screening is unknown. Detection of a microdeletion would require diagnostic testing using microarray of fetal cells obtained from chorionic villus sampling or amniocentesis.
- 8.13** Several systemic reviews and meta-analyses of studies on the diagnostic accuracy of sequencing based tests for the detection of fetal aneuploidies have been published. For instance, a study by Iwarsson et al in 2017, reviewed the performance of noninvasive prenatal testing (NIPT) for detection of trisomy 21, 18 and 13 (T21, T18, and T13) in a general pregnant population as well as on high risk pregnancies. In the general pregnant population, there is moderate evidence that the pooled sensitivity is 0.993 (95% CI, 0.955-0.999) and specificity was 0.999 (95% CI, 0.998-0.999) for the analysis of T21. Pooled sensitivity and specificity for T13 and T18 was not calculated in this population due to the low number of studies. In the high risk pregnant population, there is moderate evidence that the pooled sensitivities for T21 and T18 are 0.998 (95% CI, 0.981-0.999) and 0.977 (95% CI, 0.958-0.987) respectively, and low evidence that the pooled sensitivity for T13 is 0.975 (95% CI, 0.819-0.997). The pooled sensitivity for all three trisomies is 0.999 (95% CI, 0.998-0.999). The authors concluded, this is the first meta-analysis using GRADE that shows that NIPT performs well as a screen for trisomy 21 in general pregnant population. Although the false positive rate is low compared with first trimester combined screening, women should still be advised to confirm a positive result by invasive testing if termination of pregnancy is under consideration.
- 8.14** In conclusion, current published evidence demonstrates strong clinical validity for cfDNA testing for aneuploidy; the clinical utility is also well-established for “high risk” patients and less so for “low” or “average” risk patients given the infrequency of these genetic changes in these populations. Further study is necessary to determine if clinical utility and economic utility exist for “low” and “average risk” patients. In addition the evidence does not support use in multiple gestation pregnancies and the testing has not been validated in this setting. Lastly, the use of this testing for microdeletions is not supported due to the lack of clinical utility studies demonstrating meaningful action based on the findings from this testing.

## Applicable Coding

### CPT Codes

Covered codes if criteria are met:

- 81420** Fetal chromosomal aneuploidy (e.g., trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
- 81507** Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy

Non-covered codes:

- 81422** Fetal chromosomal microdeletion(s) genomic sequence analysis (e.g., DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood

### HCPCS Codes

No specific codes found

## Vendors

- **Personify**
- **HPS**

## References

1. ACOG Committee; "Committee Opinion No. 640: Cell-Free DNA Screening For Fetal Aneuploidy." *Obstet Gynecol* 126(3): e31-37 (2015).
2. American College of Obstetrics and Gynecologists (ACOG) (2022) "Non-Invasive Prenatal Testing". Accessed August 5, 2022. Available at: <https://www.acog.org/advocacy/policy-priorities/non-invasive-prenatal-testing/current-acog-guidance>
3. Ashoor, G, Syngelaki, A, Wagner, M, et al. (2012). Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. *Am J Obstet Gynecol*. 206. 4:322 e1-5.
4. Ashwood, ER, LaGrave, D, South, ST. (2011). *Prenatal Screening and Diagnosis*. ARUP Laboratories. Last Update: December 2011. Available: <http://www.arupconsult.com/Topics/PrenatalScreenDx.html#>. Date Accessed: June 10, 2012.
5. Benn, P., H. Cuckle, et al. (2013). "Non-invasive prenatal testing for aneuploidy: current status and future prospects." *Ultrasound Obstet Gynecol* 42(1): 15-33.
6. Benn P, Rebarber A. Non-invasive prenatal testing in the management of twin pregnancies. *Prenat Diagn*. 2021 Sep;41(10):1233-1240. doi: 10.1002/pd.5989. Epub 2021 Jun 25. PMID: 34170028; PMCID: PMC8518532.
7. Bianchi, DW, Platt, LD, Goldberg, JD, et al. (2012). Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. *Obstet Gynecol*. 119. 5:890-901.
8. *Bulletins, ACoP*. (2016). ACOG Practice Bulletin No. 163: Screening for Fetal Aneuploidy. *Obstet Gynecol*. 127:e123-137.
9. Canick, J. A., E. M. Kloza, G. M. Lambert-Messerlian, J. E. Haddow, M. Ehrich, D. van den Boom, A. T. Bombard, C. Deciu and G. E. Palomaki (2012). "DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations." *Prenat Diagn* 32(8): 730-734.
10. Canick, JA, Kloza, EM, Lambert-Messerlian, GM, et al. (2012). DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. *Prenat Diagn*. 1-5.
11. Chen, EZ, Chiu, RW, Sun, H, et al. (2011). Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. *PLoS One*. 6. 7:e21791.

12. Chiu, RW, Akolekar, R, Zheng, YW, et al. (2011). Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. *BMJ*. 342. c7401.
13. Chiu, RW, Chan, KC, Gao, Y, et al. (2008). Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. *Proc Natl Acad Sci U S A*. 105. 51:20458-63.
14. Chiu, RW, Sun, H, Akolekar, R, et al. (2010). Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of trisomy 21. *Clin Chem*. 56. 3:459-63.
15. Ehrich, M, Deciu, C, Zwiefelhofer, T, et al. (2011). Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. *Am J Obstet Gynecol*. 204. 3:205 e1-11.
16. Faas, BH, de Ligt, J, Janssen, I, et al. (2012). Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells. *Expert Opin Biol Ther*. 12 Suppl 1. S19-26.
17. Garfield, SS, Armstrong, S. (2012). Clinical and Cost Consequences of Incorporating a Novel Non-Invasive Prenatal Test into the Diagnostic Pathway for Fetal Trisomies. *Journal of Managed Care Medicine*. 15. 2:34-41.
18. Gil M.M., et al. (2017). Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. *Ultrasound Obstet Gynecol*. 2017 Sep;50(3):302-314.
19. Grace, M. R., et al. (2016). "Cell-Free DNA Screening: Complexities and Challenges of Clinical Implementation." *Obstet Gynecol Surv* 71(8): 477-487.
20. Guo, Q, Zhou, Y, Wang, X, et al. (2010). Simultaneous detection of trisomies 13, 18, and 21 with multiplex ligation-dependent probe amplification-based real-time PCR. *Clin Chem*. 56. 9:1451-9.
21. Hayes, Inc. (2021) "Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Chromosomal Copy Number Variants". February 23, 2022. Annual Review: March 30, 2023. Accessed: July 31, 2023. Available at: <https://evidence.hayesinc.com/report/gti.nipsmicro4046>
22. Hayes, Inc. (2021) "Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Trisomy 21, 18, and 13 in Women with Singleton Pregnancy". July 7, 2021. Accessed: August 5, 2022. Available at: <https://evidence.hayesinc.com/report/gti.nips4037>
23. Hayes, Inc. (2021) "Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Trisomy 21, 18, and 13 in Women with Twin Pregnancies". July 7, 2021. Annual Review: October 14, 2022. Accessed: July 31, 2023. Available at: <https://evidence.hayesinc.com/report/pmu.cfdnatwin5134>
24. Hayes, Inc. (2021) "Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Rare Autosomal Trisomies". December 21, 2021. Annual Review: October 17, 2022. Accessed: July 27, 2023. Available at: <https://evidence.hayesinc.com/report/gti.nipshigh4047>
25. Hayes, Inc. (2021) "Cell-Free DNA (cfDNA) [Formerly NIPS, NIPT] Screening for Fetal Sex Chromosome Aneuploidy" September 23, 2021. Annual Review: October 20, 2022. Accessed: July 31, 2023. Available at: <https://evidence.hayesinc.com/report/gti.nipssex4045>
26. Hill, M, Barrett, AN, White, H, et al. (2012). Uses of cell free fetal DNA in maternal circulation. *Best Pract Res Clin Obstet Gynaecol*.
27. Huang, X., J. Zheng, M. Chen, Y. Zhao, C. Zhang, L. Liu, W. Xie, S. Shi, Y. Wei, D. Lei, C. Xu, Q. Wu, X. Guo, X. Shi, Y. Zhou, Q. Liu, Y. Gao, F. Jiang, H. Zhang, F. Su, H. Ge, X. Li, X. Pan, S. Chen, F. Chen, Q. Fang, H. Jiang, T. K. Lau and W. Wang (2014). "Noninvasive prenatal testing of trisomies 21 and 18 by massively parallel sequencing of maternal plasma DNA in twin pregnancies." *Prenat Diagn* 34(4): 335-340.
28. Innatal prenatal screen information available at: <https://www.progenity.com/tests/innatal>
29. warsson E, Jacobsson B, Dagerhamn J, et. al. Analysis of cell-free fetal DNA in maternal blood for detection of trisomy 21, 18, and 13 in general pregnant population and in a high risk population – a systematic review and meta-analysis. *Acta Obstet Gynecol Scan*. Jan 2017;96(1):7-18. PMID 27779757
30. Jensen, TJ, Dzakula, Z, Deciu, C, et al. (2012). Detection of microdeletion 22q11.2 in a fetus by next-generation sequencing of maternal plasma. *Clin Chem*. 58. 7:1148-51.
31. Kalia, S. S., et al. (2017). "Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics." *Genet Med* 19(2): 249-255.
32. Khalil, A., et al. (2021). "Noninvasive prenatal screening in twin pregnancies with cell-free DNA using the IONA test: a prospective multicenter study." *Am J Obstet Gynecol* **225**(1): 79 e71-79 e13.
33. Langlois, S., J. A. Brock, et al. (2013). "Current status in non-invasive prenatal detection of down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma." *J Obstet Gynaecol Can* 35(2): 177-181.

34. Lau, TK, Chen, F, Pan, X, et al. (2012). Noninvasive prenatal diagnosis of common fetal chromosomal aneuploidies by maternal plasma DNA sequencing. *J Matern Fetal Neonatal Med.* 25. 8:1370-4.
35. Liao, GJ, Lun, FM, Zheng, YW, et al. (2011). Targeted massively parallel sequencing of maternal plasma DNA permits efficient and unbiased detection of fetal alleles. *Clin Chem.* 57. 1:92-101.
36. Mladenka C. Noninvasive prenatal screening using cell-free DNA. *J Am Assoc Nurse Pract.* 2022 Jun 1;34(6):789-791. doi: 10.1097/JXX.0000000000000710. PMID: 35661095
37. Norton ME et al. Cell-free DNA analysis for noninvasive examination of trisomy. *N Engl J Med* 2015;372:1589-97.
38. Norton ME, Baer RJ, Wapner RJ, et al. Cell-free DNA vs sequential screening for the detection of fetal chromosomal abnormalities. *Am J Obstet Gynecol.* 2016 Jun;214(6):727.e1-6.
39. Palomaki GE, Kloza EM, O'Brien BM, et al. The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population. *Genet Med.* 2017 Jul;19(7):778-786.
40. Palomaki, GE, Deciu, C, Kloza, EM, et al. (2012). DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. *Genet Med.* 14. 3:296-305.
41. Palomaki, GE, Kloza, EM, Lambert-Messerlian, GM, et al. (2011). DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. *Genet Med.* 13. 11:913-20.
42. Papageorgiou, EA, Karagrigoriou, A, Tsaliki, E, et al. (2011). Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. *Nat Med.* 17. 4:510-3.
43. Pergament E., et al. (2014). Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. *Obstet Gynecol* 2014;124:210-8.
44. QNatal Advanced testing information available at <https://www.questdiagnostics.com/home/physicians/testing-services/by-test-name/noninvasive/about.htm>
45. Sehnert, AJ, Rhees, B, Comstock, D, et al. (2011). Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. *Clin Chem.* 57. 7:1042-9.
46. Simpson, JL. (2012). Is cell-free fetal DNA from maternal blood finally ready for prime time? *Obstet Gynecol.* 119. 5:883-5.
47. Society for Maternal-Fetal Medicine Publications Committee. Electronic address, e. s. o. (2015). "SMFM Statement: clarification of recommendations regarding cell-free DNA aneuploidy screening." *Am J Obstet Gynecol* 213(6): 753-754.
48. Society for Maternal-Fetal Medicine Publications Committee: Prenatal aneuploidy screening using cell-free DNA. SMFM Consult Series No. 36. *Am J Obstet Gynecol* 2015;212:711-6.
49. Sparks, AB, Struble, CA, Wang, ET, et al. (2012). Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. *Am J Obstet Gynecol.* 206. 4:319 e1-9.
50. Sparks, AB, Wang, ET, Struble, CA, et al. (2012). Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. *Prenat Diagn.* 32. 1:3-9.
51. Stumm, M, Entezami, M, Trunk, N, et al. (2012). Noninvasive prenatal detection of chromosomal aneuploidies using different next generation sequencing strategies and algorithms. *Prenat Diagn.* 32. 6:569-77.
52. Susman, MR, Amor, DJ, Muggli, E, et al. (2010). Using population-based data to predict the impact of introducing noninvasive prenatal diagnosis for Down syndrome. *Genet Med.* 12. 5:298-303.
53. Taylor-Phillips S, Freeman K, Geppert J, et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards, and Patau syndromes: a systematic review and meta-analysis. *BMJ Open* Jan 18 2016;6(1):e010002. PMID 26781507
54. UpToDate® (2022). "Prenatal screening for common aneuploidies using cell-free DNA". Literature review current through June 2023. Last updated: April 17, 2023. Topic 458. Version 112.0. Accessed: July 31, 2023. Available at: <https://www.uptodate.com/>
55. van den Oever, JM, Balkassmi, S, Verweij, EJ, et al. (2012). Single molecule sequencing of free DNA from maternal plasma for noninvasive trisomy 21 detection. *Clin Chem.* 58. 4:699-706.
56. Verweij, EJ, van den Oever, JM, de Boer, MA, et al. (2012). Diagnostic accuracy of noninvasive detection of fetal trisomy 21 in maternal blood: a systematic review. *Fetal Diagn Ther.* 31. 2:81-6.

57. Walsh, J. (2012) Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing: a technology assessment. *Prenat Diagn.* 2013 Jun; 33(6):514-20.
58. Wright, CF, Burton, H. (2009). The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. *Hum Reprod Update.* 15. 1:139-51.
59. Zhang H, Gao Y, Jiang F, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. *Ultrasound Obstet Gynecol.* 2015 May;45(5):530-8.

Review/Revision/Approval History	
Date	Description
01/01/2024	New Policy
01/01/2025	Coverage for screening
03/23/2026	Code 81479 removed

**Disclaimer**

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult appropriate healthcare providers for medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member’s benefit plan, effective when services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Including or excluding a procedure, diagnosis, or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as they apply to an individual member.

Mountain Health Co-Op makes no representations and accepts no liability regarding the content of any external information cited or relied upon in this policy. Mountain Health Co-Op updates its Coverage Policies regularly and reserves the right to amend these policies and give notice per State and Federal requirements. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Mountain Health Co-Op.

”Mountain Health Co-Op” and its accompanying logo and marks are protected and registered trademarks of Mountain Health Co-Op. The content of this Service is proprietary and protected by copyright. You may access the copyrighted content of this Service only for purposes outlined in these Conditions of Use.

© CPT Only – American Medical Association